Using short-term response information to facilitate adaptive randomization for survival clinical trials
- PMID: 19326367
- PMCID: PMC2883264
- DOI: 10.1002/sim.3578
Using short-term response information to facilitate adaptive randomization for survival clinical trials
Abstract
Increased survival is a common goal of cancer clinical trials. Owing to the long periods of observation and follow-up to assess patient survival outcome, it is difficult to use outcome-adaptive randomization in these trials. In practice, often information about a short-term response is quickly available during or shortly after treatment, and this short-term response is a good predictor for long-term survival. For example, complete remission of leukemia can be achieved and measured after a few cycles of treatment. It is a short-term response that is desirable for prolonging survival. We propose a new design for survival trials when such short-term response information is available. We use the short-term information to 'speed up' the adaptation of the randomization procedure. We establish a connection between the short-term response and the long-term survival through a Bayesian model, first by using prior clinical information, and then by dynamically updating the model according to information accumulated in the ongoing trial. Interim monitoring and final decision making are based upon inference on the primary outcome of survival. The new design uses fewer patients, and can more effectively assign patients to the better treatment arms. We demonstrate these properties through simulation studies.
(c) 2009 John Wiley & Sons, Ltd.
Similar articles
-
Bayesian enrichment strategies for randomized discontinuation trials.Biometrics. 2012 Mar;68(1):203-11. doi: 10.1111/j.1541-0420.2011.01623.x. Epub 2011 Jun 29. Biometrics. 2012. PMID: 21714780 Free PMC article.
-
Sequential monitoring of randomization tests: stratified randomization.Biometrics. 2007 Sep;63(3):865-72. doi: 10.1111/j.1541-0420.2006.00735.x. Biometrics. 2007. PMID: 17825016
-
An oncology clinical trial design with randomization adaptive to both short- and long-term responses.Stat Methods Med Res. 2019 Jul;28(7):2015-2031. doi: 10.1177/0962280217744816. Epub 2017 Dec 12. Stat Methods Med Res. 2019. PMID: 29233085
-
A group sequential, response-adaptive design for randomized clinical trials.Control Clin Trials. 2003 Oct;24(5):506-22. doi: 10.1016/s0197-2456(03)00092-8. Control Clin Trials. 2003. PMID: 14500050 Review.
-
Re-randomization tests in clinical trials.Stat Med. 2019 May 30;38(12):2292-2302. doi: 10.1002/sim.8093. Epub 2019 Jan 22. Stat Med. 2019. PMID: 30672002 Review.
Cited by
-
A Bayesian adaptive biomarker stratified phase II randomized clinical trial design for radiotherapies with competing risk survival outcomes.Stat Methods Med Res. 2024 Jan;33(1):80-95. doi: 10.1177/09622802231215801. Epub 2023 Dec 7. Stat Methods Med Res. 2024. PMID: 38062757
-
Bayesian adaptive design for covariate-adaptive historical control information borrowing.Stat Med. 2023 Dec 20;42(29):5338-5352. doi: 10.1002/sim.9913. Epub 2023 Sep 26. Stat Med. 2023. PMID: 37750361 Free PMC article.
-
Evolution of Phase II Oncology Trial Design: from Single Arm to Master Protocol.Ther Innov Regul Sci. 2023 Jul;57(4):823-838. doi: 10.1007/s43441-023-00500-w. Epub 2023 Mar 4. Ther Innov Regul Sci. 2023. PMID: 36871111 Review.
-
A Bayesian hierarchical monitoring design for phase II cancer clinical trials: Incorporating information on response duration into monitoring rules.Stat Med. 2021 Sep 20;40(21):4629-4639. doi: 10.1002/sim.9084. Epub 2021 Jun 7. Stat Med. 2021. PMID: 34101217 Free PMC article.
-
Response adaptive randomization procedures in seamless phase II/III clinical trials.J Biopharm Stat. 2020;30(1):3-17. doi: 10.1080/10543406.2019.1657439. Epub 2019 Aug 27. J Biopharm Stat. 2020. PMID: 31454295 Free PMC article.
References
-
- Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nature Reviews Drug Discovery. 2004;3:711–715. - PubMed
-
- Pocock SJ. Group sequential methods in design and analysis of clinical trials. Biometrika. 1997;64:191–200.
-
- O’Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35:549–556. - PubMed
-
- Kim K, Demets DL. Design and analysis of group sequential tests based on the type I error spending rate function. Biometrika. 1987;74:149–154.
-
- Simon R. Optimal 2-stage designs for phase-II clinical trials. Controlled Clinical Trials. 1989;10:1–10. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources